|
| | Nedaplatin Basic information |
| | Nedaplatin Chemical Properties |
| storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | H2O : 13.6 mg/mL (44.86 mM; Need ultrasonic and warming; DMSO can inactivate Nedaplatin's activity)DMF : < 1 mg/mL (insoluble; DMSO can inactivate Nedaplatin's activity) | | form | Powder |
| | Nedaplatin Usage And Synthesis |
| Description | Nedaplatin, a novel second generation platinum complex, was marketed
in Japan for the treatment of a variety of cancers including: head and neck, small-cell
and non-small cell lung, oesophageal, prostatic, testicular, ovarian, cervical, bladder,
and uterine cancers. Platinum anticancer agents, prototyped by cisplatin, have been
reported to be hydrolyzed to the mono- or diaquated species of diamine platinum which
react with nucleophilic sites on DNA to cause intrastrand and interstrand crosslinks and
DNA-protein crosslinks, which result in cytotoxicity. Nedaplatin was reportedly more
active than cisplatin against several solid tumors while sharing less nephro- and
gastrointestinal toxicity to cisplatin in viva The minimal renal toxicity displayed by
nedaplatin allows its use in patients with deteriorated renal function. | | Originator | Shionogi (Japan) | | Uses | anticancer | | Uses | Nedaplatin is a platinum complex that has potent antineoplatic activity. | | Brand name | Aqupla | | Pharmaceutical Applications | Nedaplatin, cis-diammineglycolatoplatinum(II), is structurally similar to carboplatin.
The chemical structure consists of a central platinum(II) atom with two cis-ammonia groups as nonleaving
groups and – in contrast to carboplatin – the dianionic form of glycolic acid as the leaving group. Nedaplatin
has been approved for the clinical use in the Japanese market for the treatment of head and neck, testicular,
ovarian, lung and cervical cancer. It is typically administered by IV injection and its dose-limiting side effect
is myelosuppression. |
| | Nedaplatin Preparation Products And Raw materials |
|
